{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-065292","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.858212+00:00","generated_at":"2026-05-31T12:37:32.514397+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL","bullets":["First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.","Target indication: relapsed/refractory B-cell Non-Hodgkin's Lymphomas (R/R B-cell NHL).","Trial is open-label, dose escalation/expansion to assess safety and determine Recommended Phase II Dose (RP2D).","Principal Investigator: Naseem Esteghamat, M.D., at UC Davis Comprehensive Cancer Center.","Clinical trial identifier on ClinicalTrials.gov: NCT06343311."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-065292","json":"https://secwatch.observer/filing/0001213900-24-065292.json","markdown":"https://secwatch.observer/filing/0001213900-24-065292.md","text":"https://secwatch.observer/filing/0001213900-24-065292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024065292/0001213900-24-065292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390024065292/ea021066101-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:37:32.514397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}